FMP
NASDAQ
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
1.76 USD
0.06 (3.41%)
Valuation Date:
May 1, 2024 4:00 PM
Share Price on Valuation Date
$1.76
Stock Beta
1.527
Shares Outstanding
4054859